INSM1 Staining in Melanoma Masquerading as Small Cell Tumor
INSM1 positivity in a melanoma mimicking small cell carcinoma should be interpreted with extreme caution, as INSM1 is a neuroendocrine marker that can be positive in neuroendocrine tumors but should be negative in melanoma—the critical diagnostic panel must include SOX10, S-100, and Melan-A to confirm melanocytic origin, as these will be positive in melanoma but negative in small cell carcinoma.
Understanding the Diagnostic Challenge
When confronting a small cell tumor morphologically, the differential diagnosis primarily includes small cell lung carcinoma (SCLC), Merkel cell carcinoma (MCC), and rarely, small cell variants of melanoma. The 2023 ESMO guidelines emphasize that synaptophysin and/or INSM1 staining must be carried out in high-grade tumors that resemble small-cell carcinomas 1. However, this recommendation assumes you're working up a neuroendocrine tumor, not melanoma.
INSM1 Performance Characteristics
INSM1 has emerged as a highly sensitive neuroendocrine marker with 94.9% sensitivity for SCLC and 96.4% overall sensitivity across thoracic neuroendocrine tumors 2. Multiple studies confirm INSM1's superior performance compared to traditional markers like chromogranin A, synaptophysin, and CD56 3, 2. The nuclear staining pattern makes interpretation easier than cytoplasmic markers, particularly in high-grade tumors 4.
Critical Distinction: Melanoma vs. Neuroendocrine Tumors
Melanoma should be negative for INSM1. The 2001 melanoma guidelines specify that immunohistochemistry can confirm the melanocytic nature of a cutaneous lesion with an unusual presentation but emphasize melanocytic markers 5. The key is recognizing that:
- Melanoma markers: S-100 (highly sensitive), SOX10, Melan-A, HMB-45
- Neuroendocrine markers: INSM1, synaptophysin, chromogranin A, CD56
- These panels should be mutually exclusive
Recommended Diagnostic Algorithm
Step 1: Confirm Morphology
Examine for melanoma features: epithelioid or spindled cells, melanin pigment (though may be absent), nuclear pleomorphism, prominent nucleoli—distinct from the small cells with scant cytoplasm, nuclear molding, and salt-and-pepper chromatin of SCLC 6.
Step 2: Initial Immunohistochemical Panel
Order simultaneously:
- Melanocytic markers: SOX10, S-100, Melan-A
- Neuroendocrine markers: INSM1, synaptophysin, chromogranin A
- TTF-1: Positive in 83-100% of SCLC, negative in melanoma 7
- CK-20: Positive in 89-100% of Merkel cell carcinoma, negative in melanoma and SCLC 7
Step 3: Interpretation Framework
If SOX10/S-100 positive + INSM1 negative:
- Diagnosis: Melanoma (classic presentation)
- Proceed with melanoma staging and management
If SOX10/S-100 positive + INSM1 positive:
- This is the problematic scenario
- Consider technical artifact or cross-reactivity
- Repeat staining on different tissue block if available
- Examine staining pattern: diffuse strong nuclear INSM1 suggests true neuroendocrine differentiation (extremely rare in melanoma)
- Focal or weak INSM1 may represent aberrant expression
If SOX10/S-100 negative + INSM1 positive + TTF-1 positive:
- Diagnosis: Small cell lung carcinoma (primary or metastatic)
- Proceed with lung cancer staging 6
If SOX10/S-100 negative + INSM1 positive + CK-20 positive:
- Diagnosis: Merkel cell carcinoma
- TTF-1 should be negative 7
Common Pitfalls and Caveats
Pitfall #1: Assuming INSM1 Specificity is Absolute
While INSM1 demonstrates 97.4% specificity in genitourinary tumors 8 and high specificity in thoracic tumors 2, focal INSM1 positivity (involving <10% of tumor cells) can occur in non-neuroendocrine neoplasms 9. Recent gastric tumor data shows 36% of non-neuroendocrine neoplasms had some INSM1 positivity, though usually focal 9.
Pitfall #2: Relying on Single Markers
The 2013 ACCP guidelines emphasize that for challenging cases, a diagnostic panel of immunohistochemical assays is recommended to increase diagnostic accuracy 6. Never diagnose based on INSM1 alone.
Pitfall #3: Ignoring Clinical Context
- Melanoma: History of cutaneous primary, sun exposure, prior melanoma
- SCLC: Heavy smoking history, hilar mass with mediastinal adenopathy 10, 11
- MCC: Older white males, sun-exposed skin, rapidly growing nodule 7
Pitfall #4: Combined Tumors
Remember that up to 30% of SCLC specimens show areas of NSCLC differentiation 10, 11, and combined tumors exist. Similarly, melanoma can rarely show divergent differentiation, though neuroendocrine differentiation in melanoma is exceptionally rare.
Additional Markers for Ambiguous Cases
If the initial panel is equivocal:
- Ki-67 proliferation index: SCLC shows 50-70%, carcinoids 5-15% 6
- PRAME: Can be positive in melanoma (diagnostic aid) 12
- CD56: Positive in neuroendocrine tumors but less specific than INSM1
- Keratin pattern: Dot-like perinuclear keratin in MCC vs. diffuse in carcinomas
Clinical Impact on Management
This distinction is critical for morbidity and mortality:
- Melanoma: Surgical excision with sentinel lymph node biopsy, immunotherapy (anti-PD-1, anti-CTLA-4), targeted therapy if BRAF-mutant
- SCLC: Platinum-based chemotherapy with etoposide, concurrent thoracic radiation for limited-stage, prophylactic cranial irradiation 10, 11
- MCC: Wide local excision, sentinel lymph node biopsy, adjuvant radiation, immunotherapy for advanced disease 7
The wrong diagnosis leads to inappropriate treatment with significant impact on survival and quality of life.
When to Seek Additional Expertise
Request expert dermatopathology or thoracic pathology consultation when:
- Immunohistochemical results are discordant with morphology
- Both melanocytic and neuroendocrine markers are positive
- Clinical presentation doesn't match pathologic diagnosis
- Tissue is limited and diagnosis remains uncertain after initial workup